Neurocrine (NBIX) Shares Plunge as Data on NBI-98854 Fails to Hit Primary Endpoint
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Join SI Premium – FREE
Neurocrine Biosciences (Nasdaq: NBIX) shares have fallen more than 11 percent after data from a Phase II study of VMAT2 inhibitor NBI-98854 for tardive dyskinesia did not meet the primary endpoint.
The stock last traded at $7.88. Shares closed at $8.99.
The stock last traded at $7.88. Shares closed at $8.99.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Upgrades Neurocrine Bio. (NBIX) to Overweight 'as the Company is Knocking on the Doors of the Large-Cap Club'
- Unilever (UL) shares jump as sales growth accelerate in Q1
- Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
Create E-mail Alert Related Categories
Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
